Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04636723 · ClinicalTrials.gov registry record
Neuroinflammation in Chronic Systemic Symptoms (CSS)
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 30
- Enrollment target
NCT04636723: Completed study, sponsored by Vanderbilt University Medical Center.
NCT04636723 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04636723 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of the present research protocol is to investigate and identify translocator protein 18kDa, MRI DTI, and EEG/ERPs, markers of Chronic Systemic Symptoms (CSS).
Primary Outcome
Centralized Microglial Activation measured via mitochondrial translocator protein 18kDa (TSPO).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-02-22 |
| Est. Completion | 2021-12-07 |
What the finished NCT04636723 record still lists
NCT04636723 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04636723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04636723 about?
NCT04636723 is a clinical study titled "Neuroinflammation in Chronic Systemic Symptoms (CSS)". The purpose of the present research protocol is to investigate and identify translocator protein 18kDa, MRI DTI, and EEG/ERPs, markers of Chronic Systemic Symptoms (CSS).
What is the current status of trial NCT04636723?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2021-02-22. Estimated completion is 2021-12-07.
Who is sponsoring clinical trial NCT04636723?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI